We are live on ! Find out more
KRBP

Kiromic BioPharma, Inc. Common Stock
KRBP

Delisted

KRBP was delisted on the 13th of September, 2023.

Back to rankings

7 hedge funds and large institutions have $919K invested in Kiromic BioPharma, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
7
Holders Change
+7
Holders Change %
–
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ZCA
Zeke Capital Advisors
Pennsylvania
+$458K
2
IP
Intellectus Partners
California
+$334K
3
Citadel Advisors
Citadel Advisors
Florida
+$110K
4
TRCT
Tower Research Capital (TRC)
New York
+$57.1K
5
BlackRock
BlackRock
New York
+$33.5K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
ZCA
1
Zeke Capital Advisors
Pennsylvania
$410K +$458K +1,613 New
IP
2
Intellectus Partners
California
$299K +$334K +1,175 New
Citadel Advisors
3
Citadel Advisors
Florida
$97K +$110K +388 New
TRCT
4
Tower Research Capital (TRC)
New York
$51K +$57.1K +201 New
BlackRock
5
BlackRock
New York
$30K +$33.5K +118 New
APWA
6
Atlas Private Wealth Advisors
New Jersey
$17K +$19K +67 New
UBS Group
7
UBS Group
Switzerland
$15K +$16.5K +58 New

KRBP Hedge Fund Activity: Q4 2020 in Review

7 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kiromic BioPharma, Inc. Common Stock (KRBP) for Q4 2020, worth a combined $919K.

Buyers outnumbered sellers: 7 funds opened new KRBP positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Zeke Capital Advisors, opening a new position worth an estimated $458K.

  • 7 institutional investors held Kiromic BioPharma, Inc. Common Stock (KRBP) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $919K of Kiromic BioPharma, Inc. Common Stock stock for Q4 2020.
  • 7 funds opened new Kiromic BioPharma, Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +7 holders.
  • The largest Kiromic BioPharma, Inc. Common Stock buyer in Q4 2020 was Zeke Capital Advisors, an estimated $458K added.

Based on aggregated 13F filings for Q4 2020.